Comment: supratherapeutic response to ezetimibe administered with cyclosporine
Author:
Affiliation:
1. Professor and Chair of Pharmacy Practice College of Pharmacy Portland Campus at Oregon Health and Science University Oregon State University 840 SW Gaines Rd. Portland, OR 97239-3098 fax 503/494-8797
Publisher
SAGE Publications
Subject
Pharmacology (medical)
Link
http://journals.sagepub.com/doi/pdf/10.1345/aph.1G015a
Reference8 articles.
1. Supratherapeutic Response to Ezetimibe Administered with Cyclosporine
2. Low-density lipoprotein cholesterol reduction by SCH 58235 (ezetimibe), a novel inhibitor of intestinal cholesterol absorption in 243 hypercholesteremic subjects: Results of a dose-response study
3. Reduction of LDL Cholesterol in Patients with Primary Hypercholesterolemia by SCH 48461: Results of a Multicenter Dose-Ranging Study
4. Why some patients respond poorly to statins and how this might be remedied
Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview;Expert Opinion on Therapeutic Targets;2006-11-14
2. Current awareness: Pharmacoepidemiology and drug safety;Pharmacoepidemiology and Drug Safety;2006
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3